Baxtrostat is a first-in-class, highly selective aldosterone synthase inhibitor (ASI) developed for the treatment of resistant and uncontrolled hypertension.
It targets aldosterone synthase in its the pathophysiological role of aldosterone excess in driving sodium retention, vascular remodeling, and hypertension-mediated organ damage.
Unlike mineralocorticoid receptor antagonists (MRAs) such as spironolactone and eplerenone, which block the downstream effects of aldosterone but are limited by off-target hormonal effects and compensatory increases in renin and aldosterone, Baxtrostat directly inhibits aldosterone biosynthesis.
Baxtrostat suppresses plasma aldosterone without affecting cortisol levels, thereby minimizing the risk of adrenocortical insufficiency and other off-target endocrine effects.
This mechanism is particularly relevant for patients with resistant hypertension, where autonomous aldosterone production is a key driver of persistent blood pressure elevation despite multidrug therapy.
The antihypertensive efficacy of Baxtrostat has been established in both randomized, placebo-controlled trials enrolling patients with uncontrolled or resistant hypertension.
In the phase 2 BrigHTN trial, patients with treatment-resistant hypertension (seated BP ≥130/80 mm Hg on at least three antihypertensive agents, including a diuretic) were randomized to Baxtrostat 0.5 mg, 1 mg, 2 mg, or placebo once daily for 12 weeks:The trial was stopped early due to overwhelming efficacy at interim analysis.
There is a rapid onset and sustained nature of blood pressure reduction with Baxtrostat, with significant separation from placebo as early as week 2 and maintained through week 12.
The antihypertensive effect of Baxtrostat is durable with a slow offset and sustained effect.
Its principal safety concerns are hyperkalemia, hyponatremia, and reversible reductions in estimated glomerular filtration rate (eGFR), all mechanistically related to aldosterone synthase inhibition.
Most adverse events being mild and few leading to discontinuation.
Adverse events occurred in 47.3% of patients receiving 1 mg, 44.7% with 2 mg, and 41.3% with placebo.
Serious adverse events occurred in 1.9% (1 mg), 3.4% (2 mg), and 2.7% (placebo), with no deaths attributed to Baxtrostat.[1]
Hyperkalemia is the most clinically relevant adverse event.
In the phase 3 trial, hyperkalemia (serum potassium >5.5 mmol/L) occurred in 6.1% (1 mg) and 11.1% (2 mg) of Baxtrostat-treated patients, compared to 0.4% with placebo.
Potassium >6.0 mmol/L was confirmed in 2.3% (1 mg) and 3.0% (2 mg), versus 0.4% with placebo.
Clinical intervention for hyperkalemia was required in 2.7% (1 mg) and 7.9% (2 mg), with no cases in the placebo group.
These events were most frequent in the first two weeks of therapy and generally stabilized thereafter.
Hypotension was reported in 1.9% (1 mg) and 2.3% (2 mg) of Baxtrostat patients, compared to 0.8% with placebo, and rarely led to discontinuation.
Early, reversible reductions in eGFR were observed, with mean changes of –7.0 ml/min/1.73 m² (1 mg), –6.9 ml/min/1.73 m² (2 mg), and –0.1 ml/min/1.73 m² (placebo).
A ≥30% reduction in eGFR occurred in 12.6% (1 mg), 15.6% (2 mg), and 1.5% (placebo), while ≥50% reductions were rare (≤1.5% in any group).
These changes were generally reversible, with eGFR returning toward baseline after drug withdrawal.
No cases of adrenocortical insufficiency were reported.
Baxtrostat did not suppress cortisol levels.
Baxtrostat demonstrates rapid oral absorption, high bioavailability, and a plasma half-life of 26–31 hours, supporting once-daily dosing.
No clinically significant CYP-mediated or transporter-mediated drug-drug interactions have been identified.
Baxtrostat reduces aldosterone synthesis, thereby diminishing renal potassium excretion and increasing the risk of hyperkalemia.
The risk of hyperkalemia is amplified when Baxtrostat is used in combination with other agents that impair renal potassium excretion, such as renin-angiotensin-aldosterone system (RAAS) inhibitors (ACE inhibitors, ARBs), MRAs, and potassium-sparing diuretics (amiloride, triamterene).
Temporary discontinuation of Baxtrostat was mandated if potassium exceeded 6.0 mmol/L.
The most comprehensive long-term data for Baxtrostat supports the durability of the antihypertensive effect.
The slow offset of blood pressure reduction after discontinuationis consistent with Baxtrostat’s mechanism of action on sodium homeostasis and possibly vascular remodeling.
There were no reports of progressive or irreversible renal impairment attributable to Baxtrostat.
The most common adverse events of special interest over the long term were hyperkalemia and hyponatremia, both generally mild and reversible.
Serious adverse events were infrequent and occurred at similar rates across treatment and placebo groups.
No deaths were reported.
Baxtrostat’s efficacy and safety have been established in patients with moderate chronic kidney disease, diabetes, and elderly patients.
Baxtrostat produces clinically meaningful, dose-dependent reductions in SBP, with placebo-corrected differences of approximately 8–11 mm Hg at 1–2 mg daily dosing.
Baxtrostat selectivity and safety profile in patients with moderate CKD suggest it an option for this population.
Among patients with apparent resistant hypertension, the placebo-corrected reduction in seated SBP was 11.0 mm Hg for Baxtrostat and 9.6 mm Hg for lorundrostat, indicating a similar magnitude of antihypertensive effect for both agents.
The phase 2 Target-HTN trial also demonstrated dose-dependent reductions in SBP, with the 100 mg once-daily dose achieving a mean reduction of 14.1 mm Hg compared to 4.1 mm Hg for placebo at 8 weeks.
The safety profiles of Baxtrostat and lorundrostat are broadly similar, with both agents associated with a low incidence of serious adverse events and a predictable risk of hyperkalemia and mild, reversible reductions in eGFR.
Baxtrostat was associated with hyperkalemia (>5.5 mmol/L) in 6.1% (1 mg) and 11.1% (2 mg) of patients, compared to 0.4% in the placebo group.
Severe hyperkalemia (>6.0 mmol/L) occurred in 2.3% (1 mg) and 3.0% (2 mg), with most cases being mild, occurring early in therapy, and reversible with temporary discontinuation or dose adjustment.
Meta-analyses consistently conclude that Baxtrostat and lorundrostat have similar efficacy in lowering blood pressure in patients with resistant hypertension, with placebo-corrected reductions in SBP of approximately 9–11 mm Hg.
Both agents have a tolerable safety profile, with the principal risk being hyperkalemia, which is manageable with appropriate monitoring and dose adjustment.
No treatment-related deaths or cases of adrenocortical insufficiency have been reported for either agent.
The addition of baxtrostat therapy results in significantly lower systolic blood pressure at 12 weeks than placebo.
Baxtrostat is a highly selective aldosterone synthase inhibitor that provides clinically meaningful, dose-dependent reductions in systolic blood pressure in patients with uncontrolled and resistant hypertension.
The antihypertensive effect is robust, durable, and comparable to or exceeds that of mineralocorticoid receptor antagonists and other emerging ASIs such as lorundrostat.
The principal drug interaction concern is additive hyperkalemia with RAAS inhibitors, MRAs, or potassium-sparing diuretics, necessitating regular monitoring of serum potassium and renal function, especially in patients with impaired renal function or those receiving multiple potassium-elevating drugs.
Baxtrostat’s efficacy and safety are established in patients with moderate CKD (eGFR ≥45 mL/min/1.73 m²), diabetes, and elderly patients, but not in those with advanced CKD, severe heart failure, or other very high-risk comorbidities, where use cannot be recommended pending further studies.
Baxtrostat represents a promising, evidence-based option for patients with uncontrolled or resistant hypertension who meet the inclusion criteria of the pivotal trials, with careful attention to monitoring and management of electrolyte disturbances.